CXCR1 participates in bone cancer pain induced by Walker 256 breast cancer cells in female rats

Xu, Chengfei; Zhao, Baoxia; Xu, Long; Wang, Yahui; Liu, Beibei; Xu, Miao; He, Qing; Ni, Chaobo; Fu, Jie; Kong, Min; Lin, Xiao; Ni, Huadong; Yao, Ming

doi:10.1177/17448069221135743

Cited by 7 publications

(2 citation statements)

References 45 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The rats were allowed to acclimatize to the experimental environment for 2 days before the commencement of the study. Consistent with previous investigations, 48 , 49 , 50 the rats were anesthetized using 5 mg/mL sodium pentobarbital. All animal experiments were conducted within the time frame of 8:00 am to 8:00 pm .…”

Section: Methodsmentioning

confidence: 81%

N4-acetylcytidine acetylation of neurexin 2 in the spinal dorsal horn regulates hypersensitivity in a rat model of cancer-induced bone pain

Xu,

Zheng,

Chen

et al. 2024

Molecular Therapy - Nucleic Acids

Self Cite

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 81%

N4-acetylcytidine acetylation of neurexin 2 in the spinal dorsal horn regulates hypersensitivity in a rat model of cancer-induced bone pain

Xu,

Zheng,

Chen

et al. 2024

Molecular Therapy - Nucleic Acids

Self Cite

View full text Add to dashboard Cite

“…The role of CXCR1 in the processes of nociception remains unclear; however, recently, it was proven that this receptor is expressed by spinal cord neurons and upregulated during the development of bone cancer pain [148]. CXCR1 has four ligands: CXCL5, CXCL6, CXCL7, and CXCL8.…”

Section: Chemokines In Neuropathic Painmentioning

confidence: 99%

Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain

Pawlik

Mika

2023

Molecules

View full text Add to dashboard Cite

Neuropathic pain is a debilitating condition that affects millions of people worldwide. Numerous studies indicate that this type of pain is a chronic condition with a complex mechanism that tends to worsen over time, leading to a significant deterioration in patients’ quality of life and issues like depression, disability, and disturbed sleep. Presently used analgesics are not effective enough in neuropathy treatment and may cause many side effects due to the high doses needed. In recent years, many researchers have pointed to the important role of chemokines not only in the development and maintenance of neuropathy but also in the effectiveness of analgesic drugs. Currently, approximately 50 chemokines are known to act through 20 different seven-transmembrane G-protein-coupled receptors located on the surface of neuronal, glial, and immune cells. Data from recent years clearly indicate that more chemokines than initially thought (CCL1/2/3/5/7/8/9/11, CXCL3/9/10/12/13/14/17; XCL1, CX3CL1) have pronociceptive properties; therefore, blocking their action by using neutralizing antibodies, inhibiting their synthesis, or blocking their receptors brings neuropathic pain relief. Several of them (CCL1/2/3/7/9/XCL1) have been shown to be able to reduce opioid drug effectiveness in neuropathy, and neutralizing antibodies against them can restore morphine and/or buprenorphine analgesia. The latest research provides irrefutable evidence that chemokine receptors are promising targets for pharmacotherapy; chemokine receptor antagonists can relieve pain of different etiologies, and most of them are able to enhance opioid analgesia, for example, the blockade of CCR1 (J113863), CCR2 (RS504393), CCR3 (SB328437), CCR4 (C021), CCR5 (maraviroc/AZD5672/TAK-220), CXCR2 (NVPCXCR220/SB225002), CXCR3 (NBI-74330/AMG487), CXCR4 (AMD3100/AMD3465), and XCR1 (vMIP-II). Recent research has shown that multitarget antagonists of chemokine receptors, such as CCR2/5 (cenicriviroc), CXCR1/2 (reparixin), and CCR2/CCR5/CCR8 (RAP-103), are also very effective painkillers. A multidirectional strategy based on the modulation of neuronal–glial–immune interactions by changing the activity of the chemokine family can significantly improve the quality of life of patients suffering from neuropathic pain. However, members of the chemokine family are still underestimated pharmacological targets for pain treatment. In this article, we review the literature and provide new insights into the role of chemokines and their receptors in neuropathic pain.

show abstract

Perineural invasion: A potential driver of cancer-induced pain

Shi

Tang

et al. 2023

Biochemical Pharmacology

View full text Add to dashboard Cite

CXCR1 participates in bone cancer pain induced by Walker 256 breast cancer cells in female rats

Cited by 7 publications

References 45 publications

N4-acetylcytidine acetylation of neurexin 2 in the spinal dorsal horn regulates hypersensitivity in a rat model of cancer-induced bone pain

N4-acetylcytidine acetylation of neurexin 2 in the spinal dorsal horn regulates hypersensitivity in a rat model of cancer-induced bone pain

Targeting Members of the Chemokine Family as a Novel Approach to Treating Neuropathic Pain

Perineural invasion: A potential driver of cancer-induced pain

Contact Info

Product

Resources

About